Longeveron Inc.
LGVN Healthcare Biotechnology
Longeveron Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.2 million, down 49.9% from fiscal 2024. In the quarter to June 2026, revenue fell 9.18%, EPS grew 42.4% and free cash flow fell 49.1%, each against the same quarter a year earlier.
Follow LGVN
Longeveron Inc. (LGVN) EV/Sales
As of 16 October 2026, Longeveron Inc. (LGVN) trades at a EV/Sales of −4.2×. Over the past ten years it has ranged from −4.2× (October 2026) to 347× (November 2021) — the current reading is the lowest in ten years. That is below the Biotechnology industry median of 9.2× and below the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 3.7× | — |
| FY2024 | −0.9× | — |
| FY2023 | 34.9× | (19.52%) |
| FY2022 | 43.4× | (71.06%) |
| FY2021 | 150× | 613.59% |
| FY2020 | 21.0× | 0.00% |
| FY2019 | 21.0× | 0.00% |
| FY2018 | 21.0× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 10.8× | 21.05% |
| Mar 2026 | 8.9× | 141.70% |
| Dec 2025 | 3.7× | (1.55%) |
| Sep 2025 | 3.7× | (22.70%) |
| 23 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| CDIO Cardio Diagnostics Holdings, Inc. compare | −40.1× |
| LGVN Longeveron Inc. | −4.2× |
| XBIO Xenetic Biosciences, Inc. compare | −0.2× |
| DRMA Dermata Therapeutics, Inc. compare | n/m |
| NCNA NuCana PLC Sponsored ADR compare | n/m |
| RVPH Reviva Pharmaceuticals Holdings, Inc. compare | n/m |
| ENLV Enlivex Ltd. compare | n/m |
| PULM Pulmatrix, Inc. compare | 0.8× |
| PCSA Heatwurx Inc. compare | 45.3× |
| Biotechnology industry median | 9.2× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)